BioNTech (BNTX) files Form 6-K with results to September 30, 2025

Rhea-AI Filing Summary

BioNTech SE submitted a Form 6‑K as a foreign private issuer to provide investors with a development update and its latest financial information. On November 3, 2025, the company reported its financial results for the three and nine months ended September 30, 2025, and prepared interim condensed consolidated financial statements for that period. These financial statements, along with an operating and financial review and prospects section, are included as Exhibit 99.1 to the report and are deemed filed under the Securities Exchange Act. The filing is signed on behalf of BioNTech SE by its Chief Financial Officer and Chief Operating Officer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 3, 2025, BioNTech SE (the “Company”) provided a development update and reported its financial results for the three and nine months ended September 30, 2025. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three and nine months ended September 30, 2025 are attached hereto as Exhibit 99.1 and shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and incorporated by reference herein.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramón Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramón Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: November 3, 2025

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Quarterly Report for the Three and Nine Months Ended September 30, 2025

FAQ

What did BioNTech (BNTX) report in this Form 6-K?

BioNTech SE reported a development update and its financial results for the three and nine months ended September 30, 2025, through a Form 6‑K filing.

Which financial periods are covered in BioNTech SE’s latest report?

The report covers the company’s financial results for the three and nine months ended September 30, 2025.

What documents are included as Exhibit 99.1 for BioNTech (BNTX)?

Exhibit 99.1 contains BioNTech SE’s quarterly report, including interim condensed consolidated financial statements and the operating and financial review and prospects for the three and nine months ended September 30, 2025.

Are BioNTech SE’s interim financial statements considered filed with the SEC?

Yes. The interim condensed consolidated financial statements and related review are deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed the BioNTech SE Form 6-K?

The Form 6‑K was signed on behalf of BioNTech SE by Chief Financial Officer Ramón Zapata-Gomez and Chief Operating Officer Dr. Sierk Poetting.

Which annual report form does BioNTech SE use?

BioNTech SE files its annual reports under cover of Form 20‑F.